A review of the clinical efficacy and tolerability of almotriptan in acute migraine

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 7, 2003, Pages 1157-1163

  Dodick, David W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adverse events; Almotriptan; Efficacy; Migraine; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ELETRIPTAN; ERGOT ALKALOID; FLUOXETINE; FROVATRIPTAN; KETOCONAZOLE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VERAPAMIL; ZOLMITRIPTAN;

ANGINA PECTORIS; APHASIA; ATAXIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFUSION; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; META ANALYSIS; MIGRAINE; NAUSEA AND VOMITING; NEUROTOXICITY; OPEN STUDY; PARESTHESIA; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; SPEECH DISORDER; SYNCOPE; THORAX DISEASE; VERTIGO;

EID: 0038783508     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.7.1157     Document Type: Review

References (35)

1. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine-current understanding and treatment. N. Engl. J. Med. (2002) 346:257-270.
2. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41:646-657.
3. LIPTON RB, STEWART WF: Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache (1999) 39(Suppl. 2):S20-S26.
4. GALLAGHER RM, KUNKEL R: Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache (2003) 43:36-44.
5. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633-658.
6. BOU J, DOMENECH T, PUIG J et al.: Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur. J. Pharmacol. (2000) 410:33-41.
7. BOU J, GRAS J, CORTIJO J, MORCILLO EJ, LLENAS J, PALACIOS JM: Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia (2001) 21:804-812.
8. JANSAT JM, COSTA J, SALVA P, FERNANDEZ FJ, MARTINEZ-TOBED A: Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers J. Clin. Pharmacol. (2002) 42:1303-1310.
9. CABARROCAS X, WARRINGTON SJ, JANSAT JM, ZAYAS JM, BOYCE M, FERRER P: Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia (1999) 19:363.
10. 1B/1D agonist, in healthy volunteers. Headache (1998) 38:376 (Abstract).
11. DAHLOF C, TFELT-HANSEN P, MASSIOU H, FAZEKAS A: Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology (2001) 57:1811-1817.
12. CABARROCAS X, SALVA M: Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia (1997) 17:421.
13. SALVA M, JANSAT JM, MARTINEZ-TOBED A, PALACIOS JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab. Dispos. (2003) 31:404-411.
14. CABARROCAS X, FERNANDEZ FJ, POPESCU G, JANSAT JM, MOLZ K, FERRER P: The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache (1999):346.
15. FLEISHAKER JC, HERMAN BD, CAREL BJ, AZIE NE: Interaction between ketoconazole and almotriptan in healthy volunteers. J. Clin. Pharmacol. (2003) 43(4):423-427.
16. FLEISHAKER JC, RYAN KK, CAREL BJ, AZIE NE: Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J. Clin. Pharmacol. (2001) 41:217-223.
17. FLEISHAKER JC, SISSON TA, CAREL BJ, AZIE NE: Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Pharmacol. Ther. (2000) 67:498-503.
18. FLEISHAKER JC, SISSON TA, CAREL BJ, AZIE NE: Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia (2001) 21:61-65.
19. BOYCE M, DUNN K, WARRINGTON S: Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J. Cardiovasc. Pharmacol. (2001) 37:280-289.
20. FLEISHAKER JC, MCENROE JD, AZIE NE, FRANCOM SF, CAREL BJ: Cardiovascular effect of almotriptan in treated hypertensive patients. Clin. Pharmacol. Ther. (2002) 71:169-175.
21. DODICK DW: Oral almotriptan in the treatment of migraine: safety and tolerability. Headache (2001) 41:449-455.
22. DOWSON AJ, MASSIOU H, LAINEZ JM, CABARROCAS X: Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia (2002) 22:453-461.
23. PASCUAL J, FALK RM, PIESSENS F et al.: Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia (2000) 20:588-596.
24. SPIERINGS EL, GOMEZ-MANCILLA B, GROSZ DE, ROWLAND CR, WHALEY FS, JIRGENS KJ: Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch. Neurol. (2001) 58:944-950.
25. DODICK DW: Almotriptan increases sustained pain-free outcomes in acute migraine: results from 3 controlled clinical trials. Headache (2002) 42:21-27.
26. MATHEW N: A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache (2002) 42:32-40.
27. PASCUAL J, FALK R, DOCEKAL R et al.: Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol. (2001) 45:206-213.
28. CADY RK, SHEFTELL F, LIPTON RB et al.: Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. (2000) 22:1035-1048.
29. CADY RK, LIPTON RB, HALL C, STEWART WF, O'QUINN S, GUTTERMAN D: Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache (2000) 40:792-797.
30. PASCUAL J, CABARROCAS X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache (2002) 42:28-31.
31. MATHEW NT: Early intervention with almotriptan improves pain-free and sustained pain-free responses in the treatment of acute migraine. Headache (2003) (In Press).
32. DOWSON A, MASSIOU H, LAINEZ JM, CABARROCAS X: Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache (2003) (In Press).
33. MATHEW NT: Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin. Ther. (2002) 24:520-529.
34. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358:1668-1675.
35. FERRARI MD, GOADSBY PJ, LIPTON RB: The use of multiattribute decision models in evaluating triptan treatment options in migraine. Cephalalgia (2003) (In Press).